How much funding has Ray Therapeutics raised?

Ray Therapeutics has raised $241.0M in total funding, most recently a Series B round.

Who are Ray Therapeutics's investors?

Ray Therapeutics's investors include California Institute for Technology, Novo Holdings A/S, Deerfield Management, Shiv Chaudhary, MRL Ventures Fund, Platanus Ventures.

When was Ray Therapeutics founded?

Ray Therapeutics was founded in 2021.

Where is Ray Therapeutics headquartered?

Ray Therapeutics is headquartered in Berkeley, California, United States.

What industry is Ray Therapeutics in?

Ray Therapeutics operates in Biotech, Genomics, Therapeutics.

How many employees does Ray Therapeutics have?

Ray Therapeutics has 11-50 employees.

Ray Therapeutics

Vision, Reimagined.

Berkeley, United States · Founded 2021 · $241.0M raised

Biotech

Genomics

Therapeutics

Headquarters: Berkeley, California
Employees: 11–50
Founded: 2021
Business Model: B2B

Website: raytherapeutics.com
Total Funding: $241.0M
Last Round: $125.0M Series BApr 2026
Rounds: 5

About

Ray Therapeutics is a clinical-stage biopharmaceutical company developing optogenetic gene therapies for patients with blinding diseases including retinitis pigmentosa, Stargardt's disease, and geographic atrophy. Its lead program RTx-015 received FDA Regenerative Medicine Advanced Therapy (RMAT) designation in 2026. The company's technology reprograms surviving retinal neurons to restore vision independent of genetic mutation.

Summary

Ray Therapeutics is a Biotech company based in Berkeley, United States, founded in 2021. It has raised $241.0M in total across 5 rounds, most recently a $125.0M Series B round in Apr 2026. Investors include California Institute for Technology, Novo Holdings A/S and Deerfield Management.

LinkedIn X (Twitter)